Get notified when VKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Concurrent Common Stock Offering (new) — The company is conducting a concurrent common stock offering alongside the notes, which will dilute existing shareholders and could depress the stock price.
- No Trading Market For Notes (new) — The notes are a new security with no existing market and will not be listed on any exchange, making it difficult for investors to sell them.
- Subsidiary Liabilities (new) — The notes are structurally subordinated to approximately $79.8 million of subsidiary indebtedness and other liabilities.
- Limited Covenants (new) — The indenture for the notes will not contain meaningful covenants, allowing the company to take on additional debt or other actions without noteholder protection.
- Auditor Change (new) — The company changed its independent auditor from Marcum LLP to CBIZ CPAs P.C. for the fiscal year ended December 31, 2025.
Viking Therapeutics offers convertible senior notes due 2032, terms to be determined, alongside concurrent common stock offering
Filed September 23, 2026 · ~2 min read
Key Changes
-
high
Viking Therapeutics is offering convertible senior notes due 2032, but the aggregate principal amount, interest rate, and conversion price are left blank in this preliminary prospectus supplement.
The Offering verify on EDGAR → -
high
The company is concurrently offering shares of common stock, with an underwriter option for additional shares, further diluting existing shareholders.
The Offering verify on EDGAR → -
medium
Net proceeds from both offerings will fund clinical development of VK2735 and VK3019, plus general corporate purposes.
Use of Proceeds verify on EDGAR →
5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade VKTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 26, 2026 · How we verify